Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the NHS.
The decision by health technology assessment (HTA) organisation NICE means that the tests from Myriad Genetics, Exact Sciences, and Prosigna can be used in England and Wales to guide adjuvant chemotherapy decisions for an estimated 3,000 patients with early breast cancer.
